-
Development of matrix metalloproteinase (MMP) inhibitors (MMPharma™ Project, see www.mmpharma.com)
-
Development of activators of biglycan activity (biglycan™, see www.biglycan.com)
-
Development of stem-cell based assays and cardiovascular therapies (innostem™, see www.innostem.com)
- Development of peroxynitrite scavengers
(nitroscience™, see www.nitroscience.com)
Major R&D Grants:
Purchase and installation of a small-animal ultrasonic imaging system.
Baross Gabor program, National Office for Research and Technology (INPHARMA project, awarded for 2010)Development of Innovative technology platform for the preclinical screening of metabolic diseases.
Baross Gabor program, National Office for Research and Technology (METABBET project, awarded for the period of 2009-2011)Technology transfer support of the cardiovascular R&D projects of Pharmahungary.
Baross Gabor program, National Office for Research and Technology, 2009.
Development of “dietary foods for
special medical purposes” for patients suffering from diabetes,
atherosclerosis and coronary
heart disease.
National Technology
Platform (MED-FOOD project, awarded for the period of 2008-2012)
Platform
of mouse and human embryonic stem cell-derived cardiomyocyte test
systems for drug development.
Jedlik Anyos Grant (ES2HEART
project,
awarded for the period of 2008-2010)
Development of drug
candidates based on
genomics and chemoinformatics against myocardial infarction:
inhibitors
of matrix metalloproteinases. For further information www.mmpharma.com
Jedlik Anyos Grant
(NKFP_06_A1_MMP_2006 project, awarded for the period of 2007-2010)
Modulation
of peroxynitrite-induced
myocardial damage by pharmacological and gene therapies,
and development of clinical applications of peroxynitrite
markers.
(GVOP-331-2004-04-0095_30,
awarded for the period of 2005-2007)
Major Publications of Pharmahungary:
Bencsik P, Kupai K, Giricz Z, Görbe A, Pipis J, Murlasits Z, Kocsis GF,
Varga-Orvos Z, Puskás LG, Csonka C, Csont T, Ferdinandy P. Role of iNOS and
peroxynitrite-matrix metalloproteinase-2 signaling in myocardial late
preconditioning in rats. Am J Physiol Heart Circ Physiol. 299:H512-518 (2010)
Dormán G, Cseh S, Hajdú I, Barna L, Kónya D, Kupai K, Kovács L, Ferdinandy P. Matrix metalloproteinase inhibitors: a critical appraisal of design principles and proposed therapeutic utility. Drugs. 70:949-964 (2010)
Ovize M, Baxter GF, Di Lisa F, Ferdinandy P, Garcia-Dorado D, Hausenloy DJ, Heusch G, Vinten-Johansen J, Yellon DM, Schulz R. Postconditioning and protection from reperfusion injury: where do we stand? Position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovasc Res. 87:406-423 (2010).
Gorbe A, Giricz Z, Szunyog A, Csont T, Burley DS, Baxter GF, Ferdinandy P. Role of cGMP-PKG signaling in the protection of neonatal rat cardiac myocytes subjected to simulated ischemia/reoxygenation. Basic Res Cardiol. 105:643-650 (2010).
Csonka C, Kupai K, Kocsis GF, Novák G, Fekete V, Bencsik P, Csont T, Ferdinandy P. Measurement of myocardial infarct size in preclinical studies. J Pharmacol Toxicol Methods. 61:163-170 (2010)
Kupai K, Szucs G, Cseh S, Hajdu I, Csonka C, Csont T, Ferdinandy P. Matrix metalloproteinase activity assays: Importance of zymography. J Pharmacol Toxicol Methods. 61:205-209 (2010)
Csont T, Görbe A, Bereczki E, Szunyog A, Aypar E, Tóth ME, Varga ZV, Csonka C, Fülöp F, Sántha M, Ferdinandy P. Biglycan protects cardiomyocytes against hypoxia/reoxygenation injury: Role of nitric oxide. J Mol Cell Cardiol. 48:649-652 (2010)
Kupai K, Csonka C, Fekete V, Odendaal L, van Rooyen J, Marais de W, Csont T, Ferdinandy P. Cholesterol diet-induced hyperlipidemia impairs the cardioprotective effect of postconditioning: role of peroxynitrite. Am J Physiol Heart Circ Physiol. 297:H1729-35 (2009)
Csont T, Ferdinandy P. Letter regarding article "Biglycan is
required for adaptive remodeling after myocardial infarction". Circulation 118:e521 (2008)
Kocsis GF, Pipis J, Fekete V, Kovacs-Simon A, Odendaal L, Molnar E,
Giricz Z, Janaky T, van Rooyen J, Csont T, Ferdinandy P. Lovastatin interferes with the infarct
size-limiting effect of ischemic preconditioning and postconditioning
in rat hearts. Am J Physiol
Heart Circ Physiol 294:H2406-2409 (2008)
Ferdinandy P, Schulz R, Baxter GF. Interaction
of cardiovascular risk factors with myocardial ischemia/reperfusion
injury, preconditioning and postconditioning. Pharmacol Rev 59:418-458 (2007)
Dormán G, Kocsis-Szommer K, Spadoni C, Ferdinandy P. MMP inhibitors in cardiac diseases: an
update.
Recent Patents Cardiovasc Drug Discov 2:186-194 (2007).
Csont T, Bereczki E, Bencsik P, Fodor G, Gorbe A, Zvara A, Csonka C,
Puskas LG, Santha M, Ferdinandy P.
Hypercholesterolemia increases
myocardial oxidative and nitrosative stress thereby leading to cardiac
dysfunction in apoB-100 transgenic mice.
Cardiovasc Res. 76:100-109
(2007)
Papp A, Szommer T, Barna L, Gyimesi G, Ferdinandy P, Spadoni C, Darvas
F, Fujita T, Ürge L, Dormán G. Enhanced
hit-to-lead process using bioanalogous lead evolution and
chemogenomics: application in designing selective matrix
metalloprotease inhibitors. Expert
Opin Drug Discov 2:707-723 (2007)
Bereczki E, Gonda S, Csont T, Korpos E,
Zvara A, Ferdinandy P, Santha M. Overexpression
of biglycan
in the heart of transgenic mice: an antibody microarray study.
J Proteome Res. 6:854-861(2007)
Ferdinandy P. Peroxynitrite: just an
oxidative/nitrosative stressor or a physiological regulator as well?
Br J Pharmacol 148:1-3 (2006).
Turan N, Csonka C, Csont T, Giricz Z,
Fodor G, Bencsik P, Gyongyosi M, Cakici I, Ferdinandy P.
The role of peroxynitrite in chemical
preconditioning with
3-nitropropionic acid in rat hearts.
Cardiovasc Res 70:384-390
(2006)
Br J Pharmacol 147:125-127 (2006)
Giricz Z, Lalu MM, Csonka C, Bencsik P, Schulz R, Ferdinandy P. Hyperlipidemia attenuates the infarct
size-limiting effect of ischemic preconditioning: role of matrix metalloproteinase-2 inhibition.
J Pharmacol Exp Ther 316:154-61(2006)
Ungi I, Ungi T, Ruzsa Z, Nagy E, Zimmermann Z, Csont T, Ferdinandy P. Hypercholesterolemia attenuates
the anti-ischemic effect of preconditioning during coronary angioplasty. Chest 128:1623-1628 (2005)